Radisson Blu Seaside Helsinki-version 19FEB2018
Registration mingling etc
Clinical seection - ongoing studies
Welcome - administrative
HHjH - Ulla Olsson Strömberg
Update 007 and discontinuation amendment
Mette Ilander Göran Karlsson
007 discontinuation: Lab project
Update DAStop2 and amendment
Update EuroSKI and extended follow-up amendment
HHjH - MI
BosuPeg: Clinical study and side projects
Magnus Björkholm ?
Mutations in BCR-ABL and beyond - NGS and other techniques
Introduction to the Next in CML
Mutations-genetic aberrations beyond BCR-ABL
One more speaker from FI?
Jeroen Janssen, Amsterdam
Update of work on NordDutchCML009 data
Helsinki Hotel Radisson Blue Seaside.
11.40 – 11.45 Welcome, Jesper Stentoft (DK)
11.45 – 12.30 CML - biology: Leukemia stem cells, Ph', clonal evolution, diagnostic methods (cytogenetics, FISH, RQ-PCR, IS% definition, mutation analysis), demonstration of blood smears, definition chronic phase /accelerated / blastic phase. Teacher to be determined
12.30 – 13.30: Lunch Break
13.30 – 14.15: CML – clinic: epidemiology, symptoms (incl disease phases), differential diagnosis, registries, information to patient and relatives. Patient organizations. Jesper Stentoft
14.15 – 14.30 Break
14.30 – 15.45 CML – therapy: History, TKIs (pharmacology, administration, interactions, side effects, long term toxicities, handling), response criteria, first – second, and beyond line treatment, ELN vs national guidelines, present protocols. TKI discontinuation and dose reduction. Ulla Olsson-Strömberg
15.45 – 16.00 Break
16.00 – 16.45 CML – immune therapy: α- interferon, αllogeneic stem cell transplantation, indications and results (standard, reduced intensity, haploindentical, cord blood). Tobias Gedde-Dahl
16.50 – 17.50 Case studies. Chairperson Jesper Stentoft
Motivation for the case could be:
- I found this case interesting because ....
- I would like to discuss the following feature of the case with you: ....
- This response was peculiar ...
- This side effect was surprising: ...
17.50 – 18.00 End of school and brief evaluation.
Participation in the CML school can be combined with participation in the international CML symposium on the following day, same venue.
Please consider that NCMLSG sponsors this educational activity. All participating physicians are encouraged to apply their hospital administration for travel expenses and accommodation.
Faculty: The Nordic CML school is organized by Jesper Stentoft and the faculty consists of experienced physicians with an interest in CML from the Nordic countries:
Consultant, PhD, Tobias Gedde-Dahl III, Rikshopitalet, Oslo
Consultant, PhD, Ulla Olsson-Strömberg, Akademiska Sjukhuset, Uppsala
Teacher to be determined
Professor, PhD, Jesper Stentoft, Aarhus University Hospital
Welcome and short summary of NCMLSG activities
What is happening during TKI therapy? Cellular, molecular and immunological aspects
Single-cell molecular analysis defines therapy response and immunophenotype of stem cell subpopulations in CML
CD70/CD27 interaction in CML
New risk assessment based on the immune contexture of BM microenvironment
15 min break
Novel therapies and old acquaintances
Compounds of potential for future studies in CML
Interferon in CML
Cure of CML by TKI alone?
Discontinuation- Where do we stand
Pharmaceutical company plans in CML
Pfizer, Novartis, Incyte and Cepheid
Current consensus of CML treatment
AlloSCT -Swedish experience
CML therapy in general and treatment recommendations
HHjH Perttu Koskenvesa
Meeting adjourns-Safe trip home